Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation.
J Formos Med Assoc
; 105(7): 588-93, 2006 Jul.
Article
em En
| MEDLINE
| ID: mdl-16877240
ABSTRACT
Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Vírus da Hepatite B
/
Lamivudina
/
Hepatite B Crônica
Limite:
Humans
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article